While pharma groans at the endless stream of layoffs, one headhunting firm has some encouraging news: Pharma might be cutting costs, but it's also hiring.
This year, hundreds of pharma employees have found themselves on the chopping block, and there seems to be no end in sight to the layoffs. However, one employment-consulting firm took a closer look at where displaced pharma workers are ending up, and the results were actually positive.
According to Lynn Brown, marketing vice president for Right Management, many of the industry's laid off workers are finding jobs at other pharma companies, or in jobs related to the industry, such as contract sales, research organizations, or the biotech sector.Between January 2007 and March 2008, Right Management interviewed 1,282 pharma employees who were displaced from their jobs, and found that:
Data was taken from satisfaction surveys completed by Right Management's clients; the firm did not break down the survey by job title or segment, so it's uncertain how many positions were sales, research and development, or executive level. But according to Brown, much of the downsizing comes from strategic change.
"One of the big things we find in the pharma industry is that when a company announces they're downsizing, other pharmas call us right away to say, 'If you are servicing the out-placing work for X company, could you make those candidates available to us, or set up a job fair'" said Brown.
Brown also noted that the number of former pharma employees reaching out for assistance is no bigger this year than in the last couple of years, but she said that the number of layoffs are expected to increase in the next few years. Pharma compares to the financial segment, which Right Management also covers. Both verticals have seen a major crunch in the last year, but employees in both fields are landing jobs in the same industry.
"These numbers are strong," Brown said. "It shows that people do find jobs pretty easily in pharma."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.